Inhalte
Startseite > Köpfe am DRFZ > Dr. rer. nat. Martin Schäfer

Dr. rer. nat. Martin Schäfer

Programmbereich 2, Wissenschaftliches Personal

Pharmakoepidemiologie

+49 (0)30 28460-757

martin.schaefer@drfz.de

Wissenschaftlicher Hintergrund

Seit 2021
Principal Investigator des RABBIT-Registers, Pharmakoepidemiologie, Programmbereich Epidemiologie und Versorgungsforschung, DRFZ Berlin

Seit 2017
Senior Statistician, Pharmakoepidemiologie, Programmbereich Epidemiologie und Versorgungsforschung, DRFZ Berlin

2015
Dissertation: „Finite Bayesian mixture models with applications in spatial cluster analysis and bioinformatics”

2013 – 2016
Wissenschaftlicher Mitarbeiter, Mathematisches Institut, Heinrich-Heine-Universität, Düsseldorf

2009 – 2013
Wissenschaftlicher Mitarbeiter, Fakultät Statistik, Technische Universität Dortmund, Dortmund

2002 – 2009
Diplom in Statistik, Technische Universität Dortmund, Dortmund

Gutachtertätigkeit (letzte 5 Jahre): Annals of the Rheumatic Diseases, Lancet Rheumatology, Journal of Rheumatology, RMD Open, Zeitschrift für Rheumatologie

Deutsche Region der Internationalen Biometrischen Gesellschaft e.V.

Projekte

Go to end of slider

ausgewählte Publikationen

Gehe zum Ende des Sliders
Meißner Y, Schäfer M, Albrecht K, Kekow J, Kekow J, Zinke S, Tony HP, Strangfeld A.

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.

RMD Open. 2023 Oct;9(4):e003489. doi: 10.1136/rmdopen-2023-003489. PMID: 37880180; PMCID: PMC10603345.
Machado PM, Schäfer M, Mahil SK, Liew JW, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer AC, Fautrel B, Alonso CG, Saad CGS, Griffiths CEM, Lomater C, Miceli-Richard C, Wendling D, Alpizar RD, Wiek D, Mateus EF, Sirotich E, Soriano ER, Ribeiro FM, Omura F, Rajão MF, Santos H, Dau J, Barker JN, Hausmann JS, Hyrich KL, Gensler LS, Silva L, Jacobsohn L, Carmona L, Pinheiro MM, Zelaya MD, Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace ZS, Yiu ZZN, Yazdany J, Robinson PC, Smith CH.

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.

Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14. PMID: 36787993.
Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter JG, Schmeiser T, Schulze-Koops H, Strangfeld , Voll RE, Specker C, Mueller-Ladner U.

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

RMD Open. 2021 Oct;7(3):e001896. doi: 10.1136/rmdopen-2021-001896.
Machado PM, Schäfer M, Strangfeld (Ersthelfer) A, Gossec L, Gianfrancesco MA, Lawson-Tovey S, Mateus EF, Carmona L, Hyrich KL, Robinson PC, Yazdany J.

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers.

Ann Rheum Dis. 2023 May;82(5):e114. doi: 10.1136/annrheumdis-2021-220058. Epub 2021 Feb 18. PMID: 33602795.
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM.

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219498. doi:

AG Strangfeld

Pharmakoepidemiologie